Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary results from Penn Medicine in an ongoing first-ever human clinical trial examining the safety, tolerability, and feasibility of macrophage chimeric antigen (CAR-M) have helped demonstrate the feasibility of this innovative immunotherapy, which advances the scientific groundbreaking discovery of CAR T-cell therapy. In Penn- for Solid Cancer Tumors and presents a promising new strategy in … Read more

Single-patient pilot study shows the ability of antisense oligonucleotide to suppress mutant ALS gene

Using a synthetic short chain of chemically modified nucleotides engineered at the Institute of RNA Therapeutics at UMass Chan School of Medicine, Robert H. The ALS gene known as C9ORF72 in a pilot study of a single patient. C9ORF72 is the most common cause of familial amyotrophic lateral sclerosis (ALS) and familial frontotemporal dementia (FTD). … Read more